Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.7861/clinmed.2020-0146

http://scihub22266oqcxt.onion/10.7861/clinmed.2020-0146
suck pdf from google scholar
32414711!7385758!32414711
unlimited free pdf from europmc32414711    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32414711      Clin+Med+(Lond) 2020 ; 20 (4): e72-e75
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • The renin-angiotensin system - a therapeutic target in COVID-19? #MMPMID32414711
  • Sturrock BR; Milne KM; Chevassut TJ
  • Clin Med (Lond) 2020[Jul]; 20 (4): e72-e75 PMID32414711show ga
  • COVID-19, caused by infection with SARS-CoV-2, is a disease characterised by cough, fever and fatigue, which progresses to life-threatening lung injury in approximately 5% of patients. The SARS-CoV-2 virus enters the cell via ACE2. ACE2 is a component of the renin-angiotensin system (RAS) which has an important counterregulatory effect on the classical ACE-dependent pathway. Several antihypertensives increase ACE2 expression or activity, leading to concern that this may facilitate SARS-CoV-2 entry and worsen COVID-19 disease. However, ACE2 is protective against lung injury while ANG II (which is catabolised by ACE2) is associated with lung injury both in mice and humans. We propose that medications which inhibit the RAS ACE-dependent pathway may be beneficial in treating COVID-19 and should be explored in animal models and clinical trials. Here we give an overview of the RAS pathway with respect to COVID-19 and argue that strategies which manipulate this pathway might reduce the destructive lung manifestations of COVID-19 and improve patient outcomes.
  • |*Renin-Angiotensin System[MESH]
  • |Amides/therapeutic use[MESH]
  • |Angiotensin II/*metabolism[MESH]
  • |Angiotensin Receptor Antagonists/therapeutic use[MESH]
  • |Angiotensin-Converting Enzyme 2[MESH]
  • |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]
  • |Animals[MESH]
  • |Antihypertensive Agents/*therapeutic use[MESH]
  • |Betacoronavirus/*physiology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/complications/drug therapy/*metabolism[MESH]
  • |Fumarates/therapeutic use[MESH]
  • |Humans[MESH]
  • |Lung Injury/metabolism/virology[MESH]
  • |Mice[MESH]
  • |Pandemics[MESH]
  • |Peptidyl-Dipeptidase A/*metabolism[MESH]
  • |Pneumonia, Viral/complications/drug therapy/*metabolism[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box